Overview

Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection

Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Hard-to-treat Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xiuli Zuo
Treatments:
Amoxicillin
Anti-Bacterial Agents
Antibiotics, Antitubercular
Clarithromycin
Furazolidone
Levofloxacin
Ofloxacin
Tetracycline
Tinidazole
Criteria
Inclusion Criteria:

- Patients aged 18-70 with persistent H. pylori infection.

- Patients failed at least three different standard eradication therapies
before.Previous standard eradication therapy was defined as a 10-day or 14-day
quadruple regimen designed according to Maastricht V report.

Exclusion Criteria:

- Patients treated with H2-receptor antagonist, PPI, vonoprazan,bismuth and antibiotics
in the previous 4 weeks.

- Patients with gastorectomy, acute GI bleeding and advanced gastric cancer.

- History of allergy to any of the drugs used in the study.

- Severe concomitant cardiovascular, respiratory, or endocrine diseases,clinically
significant renal or hepatic disease, hematologic disorders and any other clinically
significant medical condition that could increase risk.

- Currently pregnant or lactating.

- Severe neurologic or psychiatric disorders.

- Alcohol abuse or drug addiction.

- Patients with compliance lower than 90% in any previous treatment are not included.

- Inability to provide informed consent and other situations that could interfere with
the examination or therapeutic protocol.